Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 3 de 3
1.
Ther Deliv ; 11(8): 497-505, 2020 Aug.
Article En | MEDLINE | ID: mdl-32842914

Aim: The aim of this study is to prepare and characterize simvastatin-loaded nanoemulsions (SIM-LN) as well as evaluate their physicochemical properties and toxicity. Methodology & results: The SIM-LN were prepared, their characteristics evaluated for 30 days, and after that, the SIM-LN toxicity was evaluated using Vero cell culture and the in vivo model of Caenorhabditis elegans. The prepared SIM-LN had an average droplet size of 139 ± 22 nm, with high encapsulation rate (>98.4%). The storage at room temperature proved to be the most optimal condition. Toxicity assays demonstrated no toxicity. Conclusion: It was demonstrated that the surfactants used as emulsifiers optimized the properties without side effects, because no toxicity was measured in preliminary tests.

2.
Epilepsy Res ; 160: 106277, 2020 02.
Article En | MEDLINE | ID: mdl-32036236

Thromboxane A2 (TXA2) is an important eicosanoid in the cardiovascular system, and increasing evidence suggests that TXA2 receptors (TPs) and their ligands may constitute valuable tools for the development of neuroprotective drugs. However, the role of TPs on seizure-induced damage has not been investigated. Therefore, we evaluated the effects of SQ 29,548, a potent and selective TP antagonist-on neuromotor performance, neurodegeneration, reactive astrocytosis, and c-Fos protein immunoreactivity after pilocarpine-induced status epilepticus (SE) in mice. Adult C57BL/6 mice received intracerebroventricular SQ 29,548 injections 90 min and 24 h after pilocarpine-induced SE. We found that SQ 29,548 prevented the impairment of neuromotor performance (Neuroscore test) 48 h after pilocarpine-induced SE. Data analysis suggested the existence of two subgroups of SQ 29,548-treated post-SE animals. Eight out of 12 SQ 29,548-treated animals displayed Neuroscore values identical to those of vehicle-treated controls, and were considered SQ 29,548 responders. However, 4 out of 12 SQ 29,548-treated animals did not show any improvement in Neuroscore values, and were considered SQ 29,548 non-responders. Treatment with SQ 29,548 attenuated SE-induced increase in the number of FJC- or GFAP-positive cells in the hippocampus of SQ 29,548 responders. In addition, SQ 29,548 prevented the SE-elicited increase of c-Fos immunoreactivity in the hippocampus. In summary, our results suggest that the TP antagonist (SQ 29,548) improves neurological outcome after pilocarpine-induced SE in mice. The existence of SQ 29,548 responders and non-responders was suggested by results from the Neuroscore test. Additional studies are needed to understand the mechanisms underlying these findings, as well as the potential uses of TP antagonists in the treatment of seizure-induced damage.


Bridged Bicyclo Compounds, Heterocyclic/therapeutic use , Fatty Acids, Unsaturated/therapeutic use , Hippocampus/drug effects , Hydrazines/therapeutic use , Neuroprotective Agents/therapeutic use , Receptors, Thromboxane/antagonists & inhibitors , Status Epilepticus/drug therapy , Animals , Bridged Bicyclo Compounds, Heterocyclic/pharmacology , Disease Models, Animal , Fatty Acids, Unsaturated/pharmacology , Female , Glial Fibrillary Acidic Protein/metabolism , Hippocampus/metabolism , Hydrazines/pharmacology , Mice , Motor Activity/drug effects , Neurons/drug effects , Neurons/metabolism , Neuroprotective Agents/pharmacology , Pilocarpine , Proto-Oncogene Proteins c-fos/metabolism , Status Epilepticus/chemically induced , Status Epilepticus/metabolism
3.
Colloids Surf B Biointerfaces ; 188: 110754, 2020 Apr.
Article En | MEDLINE | ID: mdl-31887647

Naringin is a flavonoid widely known for its pharmacological properties, such as: anti-inflammatory and antioxidant ones, being an ally to avoid oxidative damage. Although naringin is an active easily found in citrus fruits, it has low bioavailability, biodistribution and also undergoes biotransformation in naringenin, limiting the described effects. The use of nanocapsules as drug carriers may increase solubility, improve biodistribution, impede the biotransformation thereof, and thus could improve the performance of naringin for use in treating neurological diseases. Therefore, the objective of this work is to produce a nanocapsule containing naringin, validate an analytical method by RP-HPLC to determination of the drug in nanoparticle and evaluate the toxicity. To that end, the blank nanocapsules (NB, without the drug) or naringin-loaded nanocapsules (NN) at the concentration of 2 mg/mL were prepared by interfacial deposition of the preformed polymer and the quantification of naringin by HPLC. Toxicity of the formulations was evaluated in vitro in rat hippocampal slices and in vivo models with C. elegans and Danio rerio (zebrafish). The analytical parameters evaluated (linearity, limit of detection and quantification, specificity, precision, accuracy and robustness) indicated adequate method to assay of naringin in nanocapsules by HPLC. There was no indication of toxicity by the nanocapsules in the evaluated biological assays.


Flavanones/chemistry , Nanocapsules/chemistry , Animals , Behavior, Animal , Caenorhabditis elegans , Models, Animal , Rats , Zebrafish
...